Stockscreener 앱 받기
2.85
7.14%
0.19
시간 외 거래:
2.84
-0.01
-0.35%
전일 마감가:
$2.66
열려 있는:
$2.67
하루 거래량:
519.85K
Relative Volume:
1.04
시가총액:
$55.54M
수익:
-
순이익/손실:
$-40.94M
주가수익비율:
-0.7422
EPS:
-3.84
순현금흐름:
$-22.97M
1주 성능:
+1.42%
1개월 성능:
-6.86%
6개월 성능:
-42.07%
1년 성능:
-73.54%
1일 변동 폭
$2.62
$2.89
1주일 범위
$2.52
$2.89
52주 변동 폭
$1.11
$11.29
Annovis Bio Inc Stock (ANVS) Company Profile
명칭
Annovis Bio Inc
전화
484-875-3192
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
ANVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.85 | 51.83M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-10-25 | 업그레이드 | Maxim Group | Hold → Buy |
| 2023-12-29 | 개시 | Canaccord Genuity | Buy |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
What analysts say about Annovis Bio Inc. stockExceptional growth trajectory - PrintWeekIndia
Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors - TipRanks
Is Annovis Bio Inc. a good long term investmentFree Consultation - Autocar Professional
What drives Annovis Bio Inc. stock priceMassive portfolio appreciation - jammulinksnews.com
Annovis Bio Inc. Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio to Present Key Findings at Alzheimer’s Association International Conference - MSN
What risks could impact Annovis Bio Inc. stock performanceCapital Growth Picks - Newser
Annovis Bio Inc. Advances Alzheimer’s Treatment with Buntanetap Study - TipRanks
Why Annovis Bio Inc. stock attracts strong analyst attentionCapital Preservation Investment Ideas - newser.com
What makes Annovis Bio Inc. stock price move sharplyFree Popular Stock Recommendations - Newser
How Annovis Bio Inc. stock performs during market volatilityCapital Growth Picks - newser.com
Annovis Bio's Volatility Trap: Why Risky Bets and Biotech Headwinds Spell Caution for Investors - AInvest
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR.com
Annovis Bio’s Alzheimer’s Study: A Potential Game-Changer for Investors? - TipRanks
Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025 - citybuzz -
Annovis Bio Plunges 10.13% on Analyst Price Target Cut - AInvest
Annovis Bio (ANVS) Stock Jumps Over 16% in Market Trading | ANVS Stock News - GuruFocus
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MSN
Annovis Bio Approves Board Elections and Auditor Appointment - TipRanks
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Yahoo Finance
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window - FinancialContent
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance - The Manila Times
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - MSN
HC Wainwright Has Optimistic View of Annovis Bio Q2 Earnings - Defense World
Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright - Defense World
Annovis Bio Inc (ANVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.32%
1.57%
자본화:
|
볼륨(24시간):